-
The risks and benefits of prophylactic aspirin in vascular disease and cancer: what is a doctor to do?
Charles H Hennekens, David J Bjorkman
Commentary: Clinical Investigation
-
The risks and benefits of prophylactic aspirin in vascular disease and cancer: what is a doctor to do?
Charles H Hennekens, David J Bjorkman
Commentary: Clinical Investigation
-
The risks and benefits of prophylactic aspirin in vascular disease and cancer: what is a doctor to do?
Charles H Hennekens, David J Bjorkman
Commentary: Clinical Investigation
-
The risks and benefits of prophylactic aspirin in vascular disease and cancer: what is a doctor to do?
Charles H Hennekens, David J Bjorkman
Commentary: Clinical Investigation
-
The risks and benefits of prophylactic aspirin in vascular disease and cancer: what is a doctor to do?
Charles H Hennekens, David J Bjorkman
Commentary: Clinical Investigation
-
The risks and benefits of prophylactic aspirin in vascular disease and cancer: what is a doctor to do?
Charles H Hennekens, David J Bjorkman
Commentary: Clinical Investigation
-
Crizotinib for the treatment of non-small-cell lung cancer with ALK gene rearrangements
Muhammad Alamgeer, Toni-Maree Rogers, Stephen B Fox, Benjamin Solomon
Review: Clinical Trail Outcomes: Clinical Investigation
-
Crizotinib for the treatment of non-small-cell lung cancer with ALK gene rearrangements
Muhammad Alamgeer, Toni-Maree Rogers, Stephen B Fox, Benjamin Solomon
Review: Clinical Trail Outcomes: Clinical Investigation
-
Crizotinib for the treatment of non-small-cell lung cancer with ALK gene rearrangements
Muhammad Alamgeer, Toni-Maree Rogers, Stephen B Fox, Benjamin Solomon
Review: Clinical Trail Outcomes: Clinical Investigation
-
Crizotinib for the treatment of non-small-cell lung cancer with ALK gene rearrangements
Muhammad Alamgeer, Toni-Maree Rogers, Stephen B Fox, Benjamin Solomon
Review: Clinical Trail Outcomes: Clinical Investigation
-
Crizotinib for the treatment of non-small-cell lung cancer with ALK gene rearrangements
Muhammad Alamgeer, Toni-Maree Rogers, Stephen B Fox, Benjamin Solomon
Review: Clinical Trail Outcomes: Clinical Investigation
-
Crizotinib for the treatment of non-small-cell lung cancer with ALK gene rearrangements
Muhammad Alamgeer, Toni-Maree Rogers, Stephen B Fox, Benjamin Solomon
Review: Clinical Trail Outcomes: Clinical Investigation
-
Considerations in the design and conduct of clinical drug trials in older cancer patients
Athanasios G Pallis
Review: Clinical Trail Outcomes: Clinical Investigation
-
Considerations in the design and conduct of clinical drug trials in older cancer patients
Athanasios G Pallis
Review: Clinical Trail Outcomes: Clinical Investigation
-
Considerations in the design and conduct of clinical drug trials in older cancer patients
Athanasios G Pallis
Review: Clinical Trail Outcomes: Clinical Investigation
-
Considerations in the design and conduct of clinical drug trials in older cancer patients
Athanasios G Pallis
Review: Clinical Trail Outcomes: Clinical Investigation
-
Considerations in the design and conduct of clinical drug trials in older cancer patients
Athanasios G Pallis
Review: Clinical Trail Outcomes: Clinical Investigation
-
Considerations in the design and conduct of clinical drug trials in older cancer patients
Athanasios G Pallis
Review: Clinical Trail Outcomes: Clinical Investigation
-
Src tyrosine kinase inhibitors in the treatment of lung cancer: rationale and clinical data
Sacha I Rothschild,Oliver Gautschi
Therapeutic Perspective: Clinical Investigation
-
Src tyrosine kinase inhibitors in the treatment of lung cancer: rationale and clinical data
Sacha I Rothschild,Oliver Gautschi
Therapeutic Perspective: Clinical Investigation
-
Src tyrosine kinase inhibitors in the treatment of lung cancer: rationale and clinical data
Sacha I Rothschild,Oliver Gautschi
Therapeutic Perspective: Clinical Investigation
-
Src tyrosine kinase inhibitors in the treatment of lung cancer: rationale and clinical data
Sacha I Rothschild,Oliver Gautschi
Therapeutic Perspective: Clinical Investigation
-
Src tyrosine kinase inhibitors in the treatment of lung cancer: rationale and clinical data
Sacha I Rothschild,Oliver Gautschi
Therapeutic Perspective: Clinical Investigation
-
Src tyrosine kinase inhibitors in the treatment of lung cancer: rationale and clinical data
Sacha I Rothschild,Oliver Gautschi
Therapeutic Perspective: Clinical Investigation
-
Developing a network in a neglected area of clinical research: the UK Dermatology Clinical Trials Network
Carron Layfield, Tessa Clarke, Kim Thomas, Hywel Williams
Clinical Trail Outcomes: Clinical Investigation
-
Developing a network in a neglected area of clinical research: the UK Dermatology Clinical Trials Network
Carron Layfield, Tessa Clarke, Kim Thomas, Hywel Williams
Clinical Trail Outcomes: Clinical Investigation
-
Developing a network in a neglected area of clinical research: the UK Dermatology Clinical Trials Network
Carron Layfield, Tessa Clarke, Kim Thomas, Hywel Williams
Clinical Trail Outcomes: Clinical Investigation
-
Developing a network in a neglected area of clinical research: the UK Dermatology Clinical Trials Network
Carron Layfield, Tessa Clarke, Kim Thomas, Hywel Williams
Clinical Trail Outcomes: Clinical Investigation
-
Developing a network in a neglected area of clinical research: the UK Dermatology Clinical Trials Network
Carron Layfield, Tessa Clarke, Kim Thomas, Hywel Williams
Clinical Trail Outcomes: Clinical Investigation
-
Developing a network in a neglected area of clinical research: the UK Dermatology Clinical Trials Network
Carron Layfield, Tessa Clarke, Kim Thomas, Hywel Williams
Clinical Trail Outcomes: Clinical Investigation
-
Vernakalant hydrochloride in the treatment of atrial fibrillation: a review of the latest clinical evidence
Alessandro Marinelli, Iacopo Ciccarelli, Alessandro Capucci
Review Article: Clinical Investigation
-
Vernakalant hydrochloride in the treatment of atrial fibrillation: a review of the latest clinical evidence
Alessandro Marinelli, Iacopo Ciccarelli, Alessandro Capucci
Review Article: Clinical Investigation
-
Vernakalant hydrochloride in the treatment of atrial fibrillation: a review of the latest clinical evidence
Alessandro Marinelli, Iacopo Ciccarelli, Alessandro Capucci
Review Article: Clinical Investigation
-
Vernakalant hydrochloride in the treatment of atrial fibrillation: a review of the latest clinical evidence
Alessandro Marinelli, Iacopo Ciccarelli, Alessandro Capucci
Review Article: Clinical Investigation
-
Vernakalant hydrochloride in the treatment of atrial fibrillation: a review of the latest clinical evidence
Alessandro Marinelli, Iacopo Ciccarelli, Alessandro Capucci
Review Article: Clinical Investigation
-
Vernakalant hydrochloride in the treatment of atrial fibrillation: a review of the latest clinical evidence
Alessandro Marinelli, Iacopo Ciccarelli, Alessandro Capucci
Review Article: Clinical Investigation
-
Data and safety monitoring boards of randomized trials: evolving principles and practical suggestions
Charles H Hennekens,David DeMets4
Review Article: Clinical Investigation
-
Data and safety monitoring boards of randomized trials: evolving principles and practical suggestions
Charles H Hennekens,David DeMets4
Review Article: Clinical Investigation
-
Data and safety monitoring boards of randomized trials: evolving principles and practical suggestions
Charles H Hennekens,David DeMets4
Review Article: Clinical Investigation
-
Data and safety monitoring boards of randomized trials: evolving principles and practical suggestions
Charles H Hennekens,David DeMets4
Review Article: Clinical Investigation
-
Data and safety monitoring boards of randomized trials: evolving principles and practical suggestions
Charles H Hennekens,David DeMets4
Review Article: Clinical Investigation
-
Data and safety monitoring boards of randomized trials: evolving principles and practical suggestions
Charles H Hennekens,David DeMets4
Review Article: Clinical Investigation